4th Quarter - Report

INDIVIOR INC for INDIVIOR INC

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR955/S285, Medicaid Reentry Act, HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act, FY2023 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022; HR 2617, Consolidated Appropriations 2023.

LobbyistCovered position, as disclosed
FRANK J. PURCELL —

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); Centers For Medicare and Medicaid Services (CMS); Office of Natl Drug Control Policy (NDCP); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2617 (117th), H.R. 7667 (117th), H.R. 1384 (117th), H.R. 7666 (117th), H.R. 955 (117th), H.R. 2067 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.